Skip to main content
    Q

    Qiagen NV (QGEN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $49.80
    -0.09 (-0.18%)

    Market Cap: $10.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Qiagen NV (QGEN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Qiagen NV (QGEN) trades at 20.5x trailing earnings and 4.9x sales. Its P/E of 20.5x is above its 5-year median of 18.5x. Its forward P/E is 15.5x. The median P/E across 10 similar companies is 33.8x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 32.3% higher over the next year. Its free cash flow yield is 4.2%.

    MultipleValue
    P/E (trailing)20.5x
    Forward P/E15.5x
    Price to sales4.9x
    Price to book3.0x
    EV/EBITDA15.9x
    Price to FCF23.9x
    EV/FCF25.8x
    PEG1.3
    FCF yield4.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 4.6% above 19.6x, its P/S is 5.8% below 5.2x and its P/B is in line.

    MultipleCurrent5-year median10-year median
    P/E20.5x18.5x19.6x
    P/S4.9x4.9x5.2x
    P/B3.0x2.8x3.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 18.2x in 2025 to 23.0x in 2018. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$44.9718.2x4.6x2.5x
    2024$44.5318.9x5.0x2.7x
    2023$43.4318.9x4.9x2.6x
    2022$49.8718.9x5.3x3.2x
    2021$55.5818.7x5.7x4.2x
    2020$52.8522.0x6.6x4.4x
    2019$33.8021.0x5.1x3.1x
    2018$34.4523.0x5.4x3.0x
    2017$30.9322.3x5.1x2.8x
    2016$28.0221.9x5.0x2.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About QGEN

    What is QGEN's forward P/E ratio?

    Qiagen NV has a forward P/E ratio of 15.5x.

    Is QGEN stock overvalued?

    GNG's valuation label for QGEN is Fairly valued. Its P/E of 20.5x compares with a median of 33.8x across 10 similar companies.

    What is QGEN's price to sales ratio?

    Qiagen NV has a price to sales ratio of 4.9x.

    What is Qiagen NV's average P/E ratio over 5 years?

    Qiagen NV's median P/E over the last 5 years is 18.5x, from 60 month-end values through Oct 2026.

    What is QGEN's PEG ratio?

    Qiagen NV has a PEG ratio of 1.3.